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Summary The cytotoxicity of three platinum complexes, cis-diamminedichloroplatinum(II) (cis-platin), cis-
dichloro-trans-dihydroxy-cis-bis (isopropylamine) platinum(IV), (CHIP) and diammine (1, 1-cyclobutane-
dicarboxylato) platinum(II) (carboplatin) on Chinese Hamster ovary (CHO) and mouse sarcoma RIF-l cells
cultured in vitro has been compared.
The tumour cell line was much more sensitive to the cytotoxic action of the three agents compared to the
CHO cell line. CHIP and carboplatin gave similar dose-response curves, both being much less toxic than
cis-platin.
The effect of thiol modification on platinum toxicity was also investigated. Substantial reduction in the
intracellular non-protein sulphydryl content markedly enhanced the cytotoxicity of CHIP but had much less
effect on carboplatin and cis-platin. Thiol depletion by diethylmaleate had a negligible effect on cis-platin
toxicity.
Cis-platin is an effective anti-tumour agent and is well
established in the clinic (Gottlieb & Drewinko, 1975; Yagoda
et al., 1976; Young et al., 1976), but has dose-limiting
nephrotoxicity (Krakoff, 1979). In order to combat the side
effects of cis-platin, second generation platinum complexes
have been developed with much less toxicity to normal tissue
(Harrap et al., 1980). Two such compounds, CHIP and
carboplatin, have emerged for clinical studies. CHIP has
reached phase II clinical trials (Wong et al., 1985), and
carboplatin, phase III clinical trials (Canetta et al., 1985).
Manipulation of intracellular thiols may be useful clini-
cally in either enhancing drug toxicity to the tumour or by
protecting against normal tissue damage to increase the
therapeutic gain. There are numerous reports that thiols can
protect animals and cells against the toxicity of alkylating
agents (Connors et al., 1964; Connors, 1966; Contractor,
1963; Walker & Smith, 1969).
Glutathione (GSH) is the major intracellular non-protein
sulphydryl (NPSH) in living cells and is generally accepted to
play a mechanistic role in cancer treatment (Arrick &
Nathan, 1984), the remaining component of NPSH is com-
prised of cysteine, y-glutamylcysteine, lipoic acid and co-
enzyme A. GSH can interact with a variety of anti-neoplastic
drugs, mainly through nucleophilic thioether formation or
oxidation-reduction reactions. To examine the effect of thiol
depletion on platinum sensitivity we have used diethyl-
maleate (DEM) or DL-buthionine-SR-sulphoximine (BSO)
prior to platinum treatment. BSO is a specific inhibitor of
glutathione biosynthesis (Griffith & Meister, 1979) and over
90% reduction in glutathione levels can be achieved in cell
culture. DEM, on the other hand, is less specific and reacts
with non-protein thiols to form a stable adduct (Bump et al.,
1982).
Materials and methods
Cell culture
Cells were routinely cultured as a monolayer in Hepes-
buffered MEM plus 15% foetal calf serum supplemented
with non-essential amino acids and glutamine (Gibco). One
hundred units ml-1 of penicillin/streptomycin were added to
the RIF-1 cultures. CHO and RIF-l cells were grown in
plastic tissue culture flasks (Nunc.) at 37°C. The RIF-I
cultures were incubated in a humidified atmosphere containing
5% CO2.
Drug treatments
Monolayers of cells were treated with fresh medium contain-
ing the required drug concentration for one hour at 37°C.
The drug was then removed and the cells were made into a
suspension using 0.01% trypsin in 0.02% EDTA for CHO
cells, and 1 mgml - protease (type IX Sigma Chem. Co.) in
complete medium for RIF-1 cells. Appropriate cell numbers
were reseeded into 25 cM2 tissue culture flasks and incubated
for either 6 days for CHO cells or 8 days for RIF-1 cells.
Colonies were stained with carbol fuchsin and the surviving
fraction determined by comparing the colonies counted in
drug-treated to untreated controls. The plating efficiencies
for the CHO and RIF-1 cell lines were approximately 90%
and 40% respectively.
Drugs
Cis-platin (Johnson Mathey), CHIP (Bristol Myers) and
carboplatin (Bristol Myers) were all freshly dissolved in
saline prior to use.
BSO was kindly supplied by Dr R.W. Middleton, Brunel
University and the Gray Laboratory of the Cancer Research
Campaign, and was dissolved in saline.
DEM (Sigma Chem. Co.) was initially diluted in absolute
alcohol at 100mM and subsequently diluted in saline.
NPSH determination
Ice-cold trichloroacetic acid was used to precipitate protein
and the supernatant was assayed spectrophotometrically for
NPSH using Ellmans reagent (1959). NPSH was measured in
control CHO and RIF-1 cells and also after 1 hour's
treatment at 37°C with a platinum dose sufficient to reduce
cell survival to 10%.
GSH determination
This was assayed spectrophotometrically by the procedure
developed by Tietze (1969).
Results
Platinum toxicity
Figures 1, 2 and 3 show the drug dose responses obtained
with cis-platin, CHIP and carboplatin on CHO and RIF-1
cells cultured in vitro. CHIP and carboplatin are very similar
in toxicity and are 40 times less toxic than cis-platin
towards CHO cells. The RIF-1 cells are much more sensitive
to all three platinum agents than are CHO cells and the
Correspondence: E. Smith.
Received 11 May 1987, and in revised form, 26 January 1988.
C The Macmillan Press Ltd., 1988 Br. J. Cancer (1988), 57, 548-552EFFECT OF THIOL DEPLETION ON PLATINUM CYTOTOXICITY 549
c
0
CO
CY)
C
(I)
0.1
0.01
c
0
4-
0)
C
Lo
0.1
0.01
5 10 1 5 20 25 30
Cisplatin conc. (pM)
Figure 1 Dose response survival curves for CHO (0) and
RIF-1 cells (0) treated with cis-platin for 1 h at 37°C. Data
points represent the mean of 3 or more experiments with the
range of values indicated.
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Figure 3 Dose response survival curves for CHO (0) and
RIF-1 cells (0) treated with carboplatin for 1 h at 37°C. Data
points represent the mean of 3 or more experiments with the
range of values indicated.
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Figure 2 Dose response survival curves for CHO (0) and
RIF-1 cells (0) treated with CHIP for 1 h at 37°C. Data points
represent the mean of 3 or more experiments with the range of
values indicated.
shoulders of the RIF survival curves were almost absent with
CHIP and carboplatin and completely absent with cis-platin.
Effect of thiol depletion on platinum toxicity
Monolayers of CHO cells were treated with 0.2mM DEM
for 2h at 37°C prior to platinum exposure for a further 1 h
at 37°C. Under these conditions the NPSH content of CHO
cells was reduced to a level such that it was no longer
detectable. DEM pretreatment did not alter the cellular
response to cis-platin (Figure 4) and potentiated carboplatin
Cisplatin conc. (>LM)
Figure 4 Cis-platin response of CHO cells after thiol depletion
either by BSO (O) or DEM (x). Data points (0) for the cis-
platin control curve are as for Figure 1. Individual data points
from several experiments on thiol-depleted cells are shown.
toxicity by reduction of the shoulder. At very high carbo-
platin doses where the survival curve begins to plateau, the
effect of thiol depletion was minimal (Figure 5). The effect
of thiol depletion by DEM pretreatment was much more
pronounced on CHIP sensitivity, reducing the Do from
200pm to 83pm (Figure 6). For comparison CHO cells were
also treated with 100 pM BSO for 24h prior to platinum
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Figure 5 Carboplatin response of CHO cells after thiol deple-
tion either by BSO (0) or DEM (x). Data points represent the
mean of 3 or more experiments with the range of values
indicated.
exposure. The results were similar to that obtained after
DEM pretreatment except for cis-platin (Figure 4) where a
modest degree of enhancement was observed (a dose modifi-
cation of 1.35).
Intracellular thiol levels
The GSH and NPSH contents of CHO and RIF-1 cells are
shown in Table I. The levels were not significantly altered
after platinum treatment.
Discussion
Carboplatin and CHIP are much less toxic in vitro on both
the normal and tumour cell lines, when compared with the
parent compound, cis-platin. In agreement with Ohnuma et
al. (1986) we found no effect of cell density on the cytotoxi-
city of cis-platin or carboplatin. However, we did find CHIP
response varied significantly with cell density, i.e. CHIP
became more cytotoxic with a decrease in cell density (data
not shown). Despite the fact that CHIP and carboplatin are
quite different in chemical structure, they exhibit similar
dose-response curves. The absence of the shoulder on the
RIF survival response may indicate that the tumour line is
less able or unable to repair sub-lethal damage induced by
platinum complexes. The greater sensitivity of RIF-1 cells to
platinum agents compared to CHO cells could be due to
differences in drug uptake (Eichlotz-Wirth & Hietel, 1986),
increased binding of platinum to DNA in the sensitive line
(Roberts & Fraval, 1978) or the ability to excise platinum
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Figure 6 CHIP response of CHO cells after thiol depletion
either by BSO (U) or DEM (x). Data points represent the mean
of 3 or more experiments with the range of values indicated.
Table I Intracellular GSH and NPSH concentrations after thiol
depletion.
GSH content NPSH content
Cell line Treatment x 10-6 nmolcell- x 10-6 nmolcell-
CHO control 8.1+1.8a 10.8+1.16a
after BSO 0.12b non detectable
after DEM 0.2b non detectable
RIF control 8.0+ 1.la 13.8+0.45a
after BSO 0.32i
bDenotes the mean of 2 determinations.
adducts from DNA (Fraval & Roberts, 1979). Cis-platin
(Roberts & Fravel, 1978) and CHIP (Edwards & Nias, 1986)
have both been shown to be preferentially cytotoxic towards
cells-in the G1 phase of the-cell 'cycle and therefore cell lines
with longer G1 phases may be more sensitive to platinum
treatment than cells with shorter G1 times. This agrees with
the cell cycle time of 24 hours in the RIF-I compared to 13-
14 hours in the CHO cells assuming cells with longer cell
cycles have longer G1 phases.
Other workers have looked at the effect of platinum
toxicity on sensitive and resistant human carcinoma cell lines
in vitro in relation to the intracellular glutathione content,
and found in some instances that resistance to platinum
agents correlated with higher levels of glutathione (Wolf et
al., 1985; Hamilton et al., 1985; Behrens et al., 1985).
However, Andrews et al. (1985) showed that their platinum
resistant line had the same glutathione content as the
sensitive cell line. Our work indicates that the RIF-1 cells
have a similar glutathione content compared to CHO cells.
Many investigators are now looking at intracellular thiol
levels with respect to drug toxicity in different cellular
systems. Care must be taken when comparing results from
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different cell lines and different laboratories because Post et
al. (1983) have shown that GSH content varies with time
after passage and serum concentration in cell culture con-
ditions. In our studies the RIF-1 and CHO cells were both
cultured in the same serum concentration and were assayed
for GSH levels 48 h after passage.
Although DEM and BSO reduce glutathione levels by
more than 90% only BSO pretreatment was able to modify
the cis-platin response. The reason for this could be that
BSO is more efficient than DEM at removing glutathione
from platinum sensitive sites.
Of the three platinum drugs only CHIP was substantially
affected by thiol depletion in CHO cells (ER= 2.4). A similar
result was also confirmed with the RIF-1 cells. Recent data
using synchronised CHO cells have shown that the cell cycle
dependence of CHIP is removed if the cells are pretreated
with BSO (Edwards, 1986). The higher oxidation state of
CHIP compared to cis-platin and carboplatin may be a
contributory factor in its modification by thiols. It has been
proposed that CHIP requires intracellular reduction to a Pt
II complex for activity (Blatter et al., 1984), also that CHIP
can be reduced by oxidised DNA (Butler et al., 1985).
However, both these processes are less likely to occur in
thiol depleted cells. To add further controversy Andrews et
al. (1985) found no effect on CHIP toxicity in human
ovarian carcinoma cells which had been previously treated
with BSO. The carcinoma cell line was 10 times more
sensitive to cis-platin than RIF-l cells and therefore poten-
tiation of CHIP by BSO might depend on the inherent
sensitivity of the cell line to CHIP such that extremely
sensitive cell lines may not be made more sensitive to CHIP
by thiol depletion.
It has been shown that thiourea can reverse Pt(II) induced
DNA cross-links and lethal lesions in isolated DNA (Filipski
et al., 1979), and that thiourea can protect cells against the
toxicity of platinum II complexes (Zwelling et al., 1979). We
have also shown that thiourea can protect against the
toxicity of cis-platin, CHIP and carboplatin (unpublished
data). Naturally occurring thiols inside the cell may also be
able to protect against platinum toxicity in a similar fashion
to thiourea but to a lesser degree. Thus reduction of
intracellular glutathione located near Pt-DNA adducts may
be responsible for enhanced platinum toxicity.
In conclusion. RIF-1 cells did not differ appreciably in
their GSH or NPSH content from CHO cells and yet they
are much more sensitive to platinum toxicity. The concen-
tration of NPSH in specific cell organelles may be more
important than the total cellular NPSH with regard to
platinum toxicity. Cellular sensitivity to Pt IV complexes can
be increased significantly in thiol depleted cells. Thiol.
depletion has little effect on Pt II complexes. As with all
chemotherapeutic drugs, effective therapy is marred by dose-
limiting toxicities and the emergence of drug resistance by
the tumour. The use of biochemical modifiers that can either
sensitize tumour cells, or minimise drug resistance, may
improve the efficacy of platinating agents. BSO is a relatively
non-toxic compound and its use in combined modality
treatments may be of some clinical benefit.
This work was supported by a grant from the Cancer Research
Campaign.
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